A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product

Standard

A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product. / Born, Stephan; Dörfel, Max Johannes; Hartjen, Philip; Haschemi Yekani, Seyed Ali; Luecke, Julia; Meutsch, Juliane Katharina; Westphal, Julie Katharina; Birkelbach, Moritz Alexander; Köhnke, Robert Helmuth; Smeets, Ralf; Krueger, Michael.

in: BIOIMPACTS, Jahrgang 9, Nr. 3, 2019, S. 161-172.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Born, S, Dörfel, MJ, Hartjen, P, Haschemi Yekani, SA, Luecke, J, Meutsch, JK, Westphal, JK, Birkelbach, MA, Köhnke, RH, Smeets, R & Krueger, M 2019, 'A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product', BIOIMPACTS, Jg. 9, Nr. 3, S. 161-172. https://doi.org/10.15171/bi.2019.20

APA

Born, S., Dörfel, M. J., Hartjen, P., Haschemi Yekani, S. A., Luecke, J., Meutsch, J. K., Westphal, J. K., Birkelbach, M. A., Köhnke, R. H., Smeets, R., & Krueger, M. (2019). A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product. BIOIMPACTS, 9(3), 161-172. https://doi.org/10.15171/bi.2019.20

Vancouver

Bibtex

@article{8ef6b2a5b3dc4afa91d38babd227e253,
title = "A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product",
abstract = "Introduction: Mesenchymal stromal/stem cells (MSCs) derived from fat tissue are an encouraging tool for regenerative medicine. They share properties similar to the bone marrow-derived MSCs, but the amount of MSCs per gram of fat tissue is 500x higher. The fat tissue can easily be digested by collagenase, releasing a heterogeneous cell fraction called stromal vascular fraction (SVF) which contains a variable amount of stromal/stem cells. In Europe, cell products like the SVF derived from fat tissue are considered advanced therapy medicinal product (ATMPs). As a consequence, the manufacturing process has to be approved via GMP-compliant process validation. The problem of the process validation for SVF is the heterogeneity of this fraction. Methods: Here, we modified existing purification strategies by adding an additional plastic adherence incubation of maximal 20 hours after SVF isolation. The resulting cell fraction was characterized and compared to SVF as well as cultivated adipose-derived stromal/stem cells (ASCs) with respect to viability and cell yield, the expression of surface markers, differentiation potential and cytokine expression. Results: Short-term incubation significantly reduced the heterogeneity of the resulting cell fraction compared to SVF. The cells were able to differentiate into adipocytes, chondrocytes, and osteoblasts. More importantly, they expressed trophic proteins which have been previously associated with the beneficial effects of MSCs. Furthermore, GMP compliance of the production process described herein was acknowledged by the national regulatory agencies (DE_BB_01_GMP_2017_1018).Conclusion: Addition of a short purification-step after the SVF isolation is a cheap and fast strategy to isolate a homogeneous uncultivated GMP-compliant cell fraction of ASCs.",
author = "Stephan Born and D{\"o}rfel, {Max Johannes} and Philip Hartjen and {Haschemi Yekani}, {Seyed Ali} and Julia Luecke and Meutsch, {Juliane Katharina} and Westphal, {Julie Katharina} and Birkelbach, {Moritz Alexander} and K{\"o}hnke, {Robert Helmuth} and Ralf Smeets and Michael Krueger",
year = "2019",
doi = "10.15171/bi.2019.20",
language = "English",
volume = "9",
pages = "161--172",
journal = "BIOIMPACTS",
issn = "2228-5652",
publisher = "Tabriz Tabriz University of Medical Sciences",
number = "3",

}

RIS

TY - JOUR

T1 - A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product

AU - Born, Stephan

AU - Dörfel, Max Johannes

AU - Hartjen, Philip

AU - Haschemi Yekani, Seyed Ali

AU - Luecke, Julia

AU - Meutsch, Juliane Katharina

AU - Westphal, Julie Katharina

AU - Birkelbach, Moritz Alexander

AU - Köhnke, Robert Helmuth

AU - Smeets, Ralf

AU - Krueger, Michael

PY - 2019

Y1 - 2019

N2 - Introduction: Mesenchymal stromal/stem cells (MSCs) derived from fat tissue are an encouraging tool for regenerative medicine. They share properties similar to the bone marrow-derived MSCs, but the amount of MSCs per gram of fat tissue is 500x higher. The fat tissue can easily be digested by collagenase, releasing a heterogeneous cell fraction called stromal vascular fraction (SVF) which contains a variable amount of stromal/stem cells. In Europe, cell products like the SVF derived from fat tissue are considered advanced therapy medicinal product (ATMPs). As a consequence, the manufacturing process has to be approved via GMP-compliant process validation. The problem of the process validation for SVF is the heterogeneity of this fraction. Methods: Here, we modified existing purification strategies by adding an additional plastic adherence incubation of maximal 20 hours after SVF isolation. The resulting cell fraction was characterized and compared to SVF as well as cultivated adipose-derived stromal/stem cells (ASCs) with respect to viability and cell yield, the expression of surface markers, differentiation potential and cytokine expression. Results: Short-term incubation significantly reduced the heterogeneity of the resulting cell fraction compared to SVF. The cells were able to differentiate into adipocytes, chondrocytes, and osteoblasts. More importantly, they expressed trophic proteins which have been previously associated with the beneficial effects of MSCs. Furthermore, GMP compliance of the production process described herein was acknowledged by the national regulatory agencies (DE_BB_01_GMP_2017_1018).Conclusion: Addition of a short purification-step after the SVF isolation is a cheap and fast strategy to isolate a homogeneous uncultivated GMP-compliant cell fraction of ASCs.

AB - Introduction: Mesenchymal stromal/stem cells (MSCs) derived from fat tissue are an encouraging tool for regenerative medicine. They share properties similar to the bone marrow-derived MSCs, but the amount of MSCs per gram of fat tissue is 500x higher. The fat tissue can easily be digested by collagenase, releasing a heterogeneous cell fraction called stromal vascular fraction (SVF) which contains a variable amount of stromal/stem cells. In Europe, cell products like the SVF derived from fat tissue are considered advanced therapy medicinal product (ATMPs). As a consequence, the manufacturing process has to be approved via GMP-compliant process validation. The problem of the process validation for SVF is the heterogeneity of this fraction. Methods: Here, we modified existing purification strategies by adding an additional plastic adherence incubation of maximal 20 hours after SVF isolation. The resulting cell fraction was characterized and compared to SVF as well as cultivated adipose-derived stromal/stem cells (ASCs) with respect to viability and cell yield, the expression of surface markers, differentiation potential and cytokine expression. Results: Short-term incubation significantly reduced the heterogeneity of the resulting cell fraction compared to SVF. The cells were able to differentiate into adipocytes, chondrocytes, and osteoblasts. More importantly, they expressed trophic proteins which have been previously associated with the beneficial effects of MSCs. Furthermore, GMP compliance of the production process described herein was acknowledged by the national regulatory agencies (DE_BB_01_GMP_2017_1018).Conclusion: Addition of a short purification-step after the SVF isolation is a cheap and fast strategy to isolate a homogeneous uncultivated GMP-compliant cell fraction of ASCs.

U2 - 10.15171/bi.2019.20

DO - 10.15171/bi.2019.20

M3 - SCORING: Journal article

VL - 9

SP - 161

EP - 172

JO - BIOIMPACTS

JF - BIOIMPACTS

SN - 2228-5652

IS - 3

ER -